These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25523299)

  • 1. Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients.
    Thi MT; Mourad M; Capron A; Tshinanu FM; Vincent MF; Wallemacq P
    Clin Biochem; 2015 Apr; 48(6):401-5. PubMed ID: 25523299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.
    Fukuda T; Goebel J; Thøgersen H; Maseck D; Cox S; Logan B; Sherbotie J; Seikaly M; Vinks AA
    J Clin Pharmacol; 2011 Mar; 51(3):309-20. PubMed ID: 20418509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
    Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
    Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid.
    Rother A; Glander P; Vitt E; Czock D; von Ahsen N; Armstrong VW; Oellerich M; Budde K; Feneberg R; Tönshoff B; Weber LT
    Eur J Clin Pharmacol; 2012 Jun; 68(6):913-22. PubMed ID: 22274404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
    Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
    Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
    Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.
    Brunet M; Martorell J; Oppenheimer F; Vilardell J; Millán O; Carrillo M; Rojo I; Corbella J
    Transpl Int; 2000; 13 Suppl 1():S301-5. PubMed ID: 11112019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mycophenolic acid on inosine monophosphate dehydrogenase (IMPDH) activity in liver transplant patients.
    Neuberger M; Sommerer C; Böhnisch S; Metzendorf N; Mehrabi A; Stremmel W; Gotthardt D; Zeier M; Weiss KH; Rupp C
    Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):543-550. PubMed ID: 31924555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period.
    Dong M; Fukuda T; Cox S; de Vries MT; Hooper DK; Goebel J; Vinks AA
    Br J Clin Pharmacol; 2014 Nov; 78(5):1102-12. PubMed ID: 24837828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients.
    Langman LJ; LeGatt DF; Halloran PF; Yatscoff RW
    Transplantation; 1996 Sep; 62(5):666-72. PubMed ID: 8830834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.
    Maiguma T; Yosida T; Otsubo K; Okabe Y; Sugitani A; Tanaka M; Oishi R; Teshima D
    J Clin Pharm Ther; 2010 Feb; 35(1):79-85. PubMed ID: 20175815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism.
    Sombogaard F; van Schaik RH; Mathot RA; Budde K; van der Werf M; Vulto AG; Weimar W; Glander P; Essioux L; van Gelder T
    Pharmacogenet Genomics; 2009 Aug; 19(8):626-34. PubMed ID: 19617864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients.
    Md Dom ZI; Coller JK; Carroll RP; Tuke J; McWhinney BC; Somogyi AA; Sallustio BC
    Br J Clin Pharmacol; 2018 Oct; 84(10):2433-2442. PubMed ID: 29974488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inosine monophosphate dehydrogenase activity and mycophenolate pharmacokinetics in children with nephrotic syndrome treated with mycophenolate mofetil.
    Sobiak J; Resztak M; Zachwieja J; Ostalska-Nowicka D
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1197-1208. PubMed ID: 35877984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization and application of an HPLC method for quantification of inosine-5'-monophosphate dehydrogenase activity as a pharmacodynamic biomarker of mycophenolic acid in Chinese renal transplant patients.
    Liu F; Xu L; Sheng C; Qiu X; Zhang M; Jiao Z
    Clin Chim Acta; 2018 Oct; 485():333-339. PubMed ID: 29964005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications.
    Weimert NA; Derotte M; Alloway RR; Woodle ES; Vinks AA
    Ther Drug Monit; 2007 Apr; 29(2):141-9. PubMed ID: 17417067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inosine monophosphate dehydrogenase activity depends on plasma concentrations of mycophenolic acid and its glucuronides in kidney transplant recipients.
    Mino Y; Naito T; Otsuka A; Ozono S; Kagawa Y; Kawakami J
    Clin Chim Acta; 2009 Nov; 409(1-2):56-61. PubMed ID: 19723513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.
    Li H; Mager DE; Sandmaier BM; Storer BE; Boeckh MJ; Bemer MJ; Phillips BR; Risler LJ; McCune JS
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1121-9. PubMed ID: 24727337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients.
    Tang JT; de Winter BC; Hesselink DA; Sombogaard F; Wang LL; van Gelder T
    Br J Clin Pharmacol; 2017 Apr; 83(4):812-822. PubMed ID: 27753146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
    Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.